BresMed at Virtual ISPOR 2021

17–20 May 2021

This year’s theme for ISPOR is “HEOR: Evolving for Tomorrow’s Challenges” While the conference is taking place virtually this year, we’re happy to still be contributing a range of workshops, panels and posters.

US ISPOR normally provides us with the chance to catch up with the people we work with throughout the year, and though this year looks different we’re also still available to chat. You can contact us if you’d like to arrange a meeting or if you are attending the virtual event you can chat with us during the event by visiting our company page.

Issue Panel

Date & time Code Title Moderator Panelists
Wednesday 19 May   13:45-14:45
(Breakout Session 3)
IP6
Real World Evidence Utilization Challenges: Building an Integrated System of RWE Data Transparency, Stakeholder Outreach and HTA Acceptance
Lucinda Orsini
Laura E. Happe, Jonathan Kowalski,  Robert J. Matheis.

Workshops

Date & time Code Title Discussion leaders
Thursday 20 May 10:00-11:00
(Breakout session 4)
 W11 Science, art or arbitrariness? Evaluating the risk of treatment waning for novel oncology therapies Raquel Aguiar-Ibáñez, Gianluca Gianluca Baio, Nick Latimer, Dawn Lee.

Posters

Session Code Title Authors
PCN: Cancer PCN31 Matching Adjusted Indirect Treatment Comparison of FGFR2+ Patients in the Fight-202 Trial VS. Patients with Unspecified FGFR2 Status Receiving Standard of Care Treatments Galeone C, Gregory J, Patterson K, Reason T, Macarulla T, Sabatelli L.
PCN: Cancer PCN44  Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable STAGE III NSCLC Patients in the US: An Update Based on 4-Year Survival DATA Seal B, Mooradian MJ, Van Keep M, Dunlop W, Brannman L, Yong C.
PSS: Sensory System Disorders PSS5 The Cost-Effectiveness of Dexamethasone Intravitreal Implant Versus Anti-Vascular Endothelial Growth Factor Therapies for Eyes with a Phakic Lens in UK Clinical Practice Lebbink E, Morgan P, Tefos F, Lowry C.
PRO: Rare & Orphan Diseases PRO15 Healthcare Resource Utilization Associated with NON-Dystrophic Myotonia: Results from a Delphi Panel Omar A, Chapman AM, Schurer M, Lee H, Ellis C.
PIN: Infectious Diseases PIN28 A US Payer Cost-Effectiveness Analysis of Imipenem/Cilastatin/Relebactam Versus Colistin PLUS Imipenem/Cilastatin in Patients with Carbapenem-Resistant Bacterial Infections Naik J, Ralph L, Massello M, Dillon R, Mccann E, Yang J.
PIN: Infectious Diseases PIN67 Real-Time Analysis of COVID-19 DATA Using Sequential Monte Carlo Methods  Sheinson D, Meng Y, Elsea D.

We’d love to talk with you, contact us to arrange a meeting.

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies